Improved oral bioavailability of cyclosporin A in male Wistar rats: Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension

International Journal of Pharmaceutics

Volumn 245, Issue 1-2, 2002, Pages 143-151

  Bravo González, Roberto Carlos ^a   Huwyler, Jörg ^a   Walter, Isabelle ^a   Mountfield, Richard ^a   Bittner, Beate ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cyclosporin A; Microsuspension; Oral bioavailability; Self dispersing formulation; Solutol HS 15

Indexed keywords

CYCLOSPORIN A; DRUG ADDITIVE; GLYCEROL; GLYCOFUROL 75; LABRAFAC CC; LABRAFAC CM 10; LABRAFIL M 2125; LABRAFIL M2125CS; LABRAFIL WL 2609; LABRASOL; MACROGOL; MACROGOL 200; MACROGOL 400; N METHYLPYRROLIDONE; N,N DIMETHYLACETAMIDE; OLEIC ACID; POLYSORBATE 20; POLYSORBATE 80; PROPYLENE GLYCOL; SESAME SEED OIL; SOLUTOL HS 15; SOYBEAN OIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TISSUE LEVEL; DRUG TRANSPORT; INTESTINE FLUID; MALE; NONHUMAN; POWDER; PRIORITY JOURNAL; RAT; STOMACH JUICE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SOLUBILITY; SOLVENTS; STEARIC ACIDS; SUSPENSIONS;

EID: 0036805875     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00339-3     Document Type: Article

References (30)

1. Bittner B., Mountfield R.J. Intravenous administration of poorly soluble new drug entities (NDEs) in early drug discovery: the potential impact of the formulation on pharmacokinetic parameters. Curr. Opin. Drug Disc. Dev. 5:2002;59-71.
2. Bravo González R.C., Mountfield R.J., Walter I., Delobel F., Bittner B. Impact of Solutol HS 15 on the clearance of midazolam in rat hepatocytes. Drug Metab. Rev. 33:2001;183.
3. Buckingham L.E., Balasubramanian M., Safa A.R., Sah H., Komarov P., Emanuele R.M., Coon J.S. Reversal of multi-drug resistance in vitro by fatty acid-PEG-fatty acid diesters. Int. J. Cancer. 65:1996;74.
4. Burcham D.L., Maurin M.B., Hausner E.A., Huang S.-M. Improved oral bioavailability of the hypercholesterolaemic DMP 565 in dogs following oral dosing in oil and glycol solutions. Biopharm. Drug Dispos. 18:1997;737-742.
5. Chang T., Benet L.Z., Herbert M.F. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 59:1996;297-303.
6. Drewe J., Beglinger C., Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br. J. Clin. Pharmacol. 33:1992;39-43.
7. Fahr A. Cyclosporin clinical pharmacokinetics. Clin. Pharmacokinet. 24:1993;472-495.
8. Fricker G., Drewe J., Huwyler J., Gutmann H., Beglinger C. Relevance of p-glycoprotein for enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 118:1996;1841-1847.
9. Friman S., Bäckman L. A new microemulsion formulation of cyclosporin. Pharmacokinetics and clinical features. Drug Dispos. 30:1996;181-193.
10. Gershanik T., Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur. J. Pharm. Biopharm. 50:2000;179-188.
11. Ismailos G., Reppas C., Dressman J.B., Macheras P. Unusual solubility behavior of cyclosporin A in aqueous media. J. Pharm. Pharmacol. 43:1991;287-289.
12. Johnston A., Marsden J.T., Hla K.K., Henry J., Holt T.W. The effect of vehicle on oral absorption of cyclosporin. Br. J. Clin. Pharmacol. 21:1986;114P.
13. Kahan B.D. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplant. Proc. 40:1985;457-476.
14. Kelly P.A., Wang H., Napoli K.L., Kahan B.D., Strobel H.W. Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur. J. Drug Metab. Pharmacokinet. 24:1999;321-328.
15. Kovarik J.M., Mueller E.A., van Bree J.B., Tetzloff W., Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 83:1994;444-446.
16. Levy G., Grant D. Potential for cyclosporin A-Neoral in organ transplantation. Transplant. Proc. 26:1994;2932-2934.
17. Lindberg-Freijs A., Karlsson M.O. Dose dependent absorption and linear disposition of cyclosporin A in rat. Biopharm. Drug Dispos. 15:1994;75-85.
18. Lown K.S., Mayo R.R., Leichtman A.B., Hsiao H.L., Turgeon K., Schmiedlin R.P., Morton B., Guo W., Rossi S.J., Benet L.Z., Watkins P.B. Role of intestinal p-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:1997;1-13.
19. Metha M., Venkataramanan R., Burckart G.J. Effect of bile on cyclosporin absorption in liver transplant patients. Br. J. Clin. Pharmacol. 25:1984;579-584.
20. Meyer J.H., Lake R., Elashoff J.D. Postcibal gastric emptying of pancreatin pellets. Effects of dose and meal oil. Dig. Dis. Sci. 46:2001;1846-1852.
21. Ptachcinski R.J., Venkataramanan R., Burckart G.J. Clinical pharmacokinetics of cyclosporine. Clin. Pharmacokinet. 11:1986;107-132.
22. Ritschel W.A., Adolph S., Ritschel G.B., Schroeder T. Improvement of peroral absorption of CyA by microemulsions. Meth. Find. Exp. Clin. Pharmacol. 12:1990;127-134.
23. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. Human p-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268:1993;6077-6080.
24. Taesch S., Niese D. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients. Transpl. Int. 7:1994;S263-S266.
25. Takada K., Shibata N., Yoshimura H., Masuda Y., Yoshikawa H., Muranishi S., Oka T. Promotion of the selective lymphatic delivery of cyclosporin A by lipid-surfactant mixed micelles. J. Pharmacobio.-Dyn. 8:1985;320-323.
26. Tjia J.F., Webber I.R., Back D.J. Cyclosporin metabolism by the gastrointestinal mucosa. Br. J. Clin. Pharmacol. 31:1991;344-346.
27. Ueda C.T., Lemaire M., Gsell G., Misslin P., Nussbaumer K. Apparent dose-dependent absorption of cyclosporin A in rats. Biopharm. Drug Dispos. 5:1984;141-151.
28. Ueda C.T., Lemaire M., Gsell G., Nussbaumer K. Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution in rats. Biopharm. Drug Dispos. 4:1983;113-124.
29. Ueda C.T., Nickols J.G., Schmelter R.F. Preliminary observations on the absorption of liposome-encapsulated drug by the intestinal lymphatics. Res. Commun. Chem. Pathol. Pharmacol. 32:1981;487-498.
30. Vernillet L., Kovalik J.M., Freiburghaus R. Blood cyclosporin A and metabolite kinetic profiles after administration of Sandimmune soft gelatin capsules and Neoral in transplant recipients. Transplant. Proc. 26:1994;2964-2968.